Chronix Biomedical’s serum DNA assays can monitor disease activity and treatment response in multiple sclerosis
Chronix Biomedical
San Jose, California, April 6, 2010 – Chronix Biomedical today announced publication of a study that supports the utility of its serum DNA blood tests to predict clinical status and monitor disease activity and response to...